# DEVELOP CGMP TECHNOLOGY FOR CRISPR/CAS GENOME EDITING OF CELLS FOR USE IN CELL-BASED IMMUNOTHERAPY FOR CANCER

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2020 · $4,033,134

## Abstract

Support to develop cGMP manufacturing capability for non-viral, genome editing of immune cells for use in cancer cell therapy indications.

## Key facts

- **NIH application ID:** 10281320
- **Project number:** 75N91019D00024-0-759102000017-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** ETHAN DMITROVSKY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $4,033,134
- **Award type:** —
- **Project period:** 2020-09-25 → 2023-09-24

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10281320

## Citation

> US National Institutes of Health, RePORTER application 10281320, DEVELOP CGMP TECHNOLOGY FOR CRISPR/CAS GENOME EDITING OF CELLS FOR USE IN CELL-BASED IMMUNOTHERAPY FOR CANCER (75N91019D00024-0-759102000017-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10281320. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*